Background: Non-inferiority clinical trials (NIFCTs) aim to demonstrate that the experimental therapy has advantages over the standard of care, with acceptable loss of efficacy. We evaluated the purposes underlying the selection of a non-inferiority design in oncology and the size of their non-inferiority margins (NIFm's).
introduction Non-inferiority clinical trials (NIFCTs) are defined as trials whose aim is to demonstrate that the experimental treatment is not clinically worse than the standard of care by more than a pre-specified boundary, termed as non-inferiority margin (NIFm) [1] . According to the International Conference on Harmonization guidelines [2] , the term non-inferiority is used when referring to a one-sided trial, i.e. when the authors are only interested to know whether the new treatment is not worse (instead of either clinically worse or better, as in twosided designs) compared with the control therapy. Such trials are useful to compare new therapies which are thought to bring advantages over the standard intervention in terms of costs, safety or more convenient schedules of administration, but with clinically acceptable loss of efficacy. In oncology, such advantages may improve patient care, particularly with respect to palliative treatments, with more gentle and/or convenient regimens. Yet, the design, implementation and analysis of an NIFCT have presented substantial challenges in the drug development process. This is because NIFCTs are often large trials, time and resource consuming and statistically complex to analyze and interpret [3] .
An important aspect involving non-inferiority designs is the proper selection of the NIFm [1, 4] . The choice of this margin is critical for the sample size calculation and depends on both knowledge of the effect of the control drug and clinical judgment [5] . Also, the NIFm should not be larger than the smallest difference between the comparator treatment and a given placebo [1, 4] . When the result of the primary end point falls within the margin of non-inferiority, the null hypothesis is rejected and the study is considered positive, i.e, noninferiority is proven. When the value of the low boundary of the confidence interval of the primary end point result falls outside of this range, the non-inferiority cannot be proven and the assumption of non-inferiority is flawed. While these strict methodological and statistical principles must be followed in order to design and report an NIFCT, as stated by the CONSORT group [6] . Many studies have not adhered to these recommendations. A systematic review of 162 NIFCTs conducted in different medical areas found concerning methodological drawbacks in the design and analyses of these trials, as for example, lack of description of the basis for sample size calculation and 7% did not even report a prespecified NIFm [7] . In oncology, a recent study of 72 NIFCTs also demonstrated serious methodological problems in reporting such as claims of non-inferiority when the design was of superiority and deficiency in reporting of the NIFm in 6% of trials [8] .
Not only statistical rigor is vital for the design of these trials, but also it is important to understand the purposes underlying their design and conduction. Conceptually, NIFCTs should offer advantages against the standard therapies. The extent to which this principle is true in the oncology field remains unknown. Here, we aimed at understanding the reasons that have driven investigators and sponsors to design NIFCTs of new oncology drugs by means of which advantage the experimental therapy would bring over the standard of care. We also looked at study characteristics such as NIFm's and their source of funding.
methods
We carried out a systematic review of all NIFCTs of cancer-directed therapies and supportive care agents in oncology published from January 2001 to January 2011 (10-year period). We searched for eligible studies published in the PubMed during this period, using the words 'noninferiority' AND 'neoplasm' OR 'cancer', limited to English language. Articles were included only if the study was a randomized, controlled trial assessing non-inferiority, participants were adult cancer patients, and the intervention was a systemic anticancer treatment or a supportive care agent. When an updated analysis of an NIFCT was identified, only the first publication was included. We complemented the search of abstracts published in the Proceedings of the American Society of Clinical Oncology (ASCO) congress from January 2005 to December 2010. For this search, we used the electronic search engine provided by ASCO, looking for abstracts which had the word 'non-inferiority' in the abstract body and/or title. We assumed that abstracts published before 2005 had already been reported in full publication by the time of our search. Articles and abstracts were screened for eligibility by two investigators (AA and LC).
Source of funding, type of tumor, total number of patients randomized, type of primary end point and their results and pre-specified NIFm's were extracted from the eligible full articles and abstracts by two investigators (AA and LC), and double checked for accuracy of data by a third investigator (RR). NIFCTs were considered positive or negative according to the pre-specified NIFm of the primary end point described in the Methods section; if the low boundary of the confidence interval of the primary end point result fell within the NIFm (P-value <0.05), the study was considered positive. The NIFm could be either determined as the prespecified low boundary of the confidence interval of the hazard ratio between the two groups when the primary outcome was a time-to-event end point or as the low boundary of the confidence interval of a proportion, when the primary end point was binary. When the NIFm used for the sample size calculation was not given, the study was considered positive or negative as per the results, taking into account P < 0.05 for the primary end point.
Then, the two investigators (AA and RR) independently evaluated the purpose of each NIFCT in order to understand the main motives that might have driven the study design. The purpose of the study was defined based on the expected advantage the experimental therapy would offer over the standard treatment. To classify such purposes, we evaluated the articles' Introduction and Discussion sections or the whole abstract text for trials published in the abstract form. Particularly because of the little information presented in abstracts, investigators' judgment, based on their oncology background, was taken into consideration to classify the abstract purposes. We classified such purposes/advantages as: 'new drug is less toxic than the standard drug' (less adverse events of any grade, or less grade 3 or 4
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Volume 24 | No. 7 | July 2013 doi:10.1093/annonc/mdt073 |  toxicity or less drug-related discontinuation), 'the new treatment offers more convenient schedule' (oral drugs or bolus administration instead of infusional or less hospital visits), 'the new therapy is less expensive than the standard of care', 'the new regimen is less dose-intense' (example: every 3 weeks instead of weekly treatments), 'the new regimen uses lesser number of drugs', 'the new treatment provides better quality of life than the standard treatment', or ' unknown purpose' (all others excluded).
Descriptive statistics was used to summarize the results.
results
The search retrieved 163 studies of which 75 were eligible (34 abstracts and 41 full articles). Eighty-eight studies were excluded (Figure 1 ), because they were not NIFCTs or were updated studies. Table 1 summarizes the main characteristics of an NIFCT. Nearly half (43%) were partially or entirely sponsored by industry. Approximately one-third of NIFCTs tested drugs for colorectal or lung cancer (n = 24; 32% each). The median number of randomized patients was 956 (range: 80-6, 296) and the most common primary end points were overall survival (n = 19; 25%) and progression-free survival (n = 15; 20%). As per the primary end point, 55 (73%) NIFCTs were positive. Among the positive trials (n = 55), 22 (40%) were partially or entirely sponsored by a for-profit organization, 9 (16%) were sponsored by a not for-profit organization and 24 (44%) did not report source of funding. Among 16 negative trials, 9 (56%) received funds from profitmaking companies, 4 (25%) were sponsored by not for-profit organizations and three did not provided information on financial support.
The pre-specified NIFm was reported in 62 (83%) NIFCTs: 22 abstracts and 40 full publications. This has not changed after the publication of the CONSORT statement in 2006: six NICFTs published in 2007 or earlier and seven NIFCTs published after 2007 did not provide their planned NIFm. For trials with a binary primary end point, the median NIFm was 12.5% (n = 28; range 4%-25%). For trials that used a time-toevent primary outcome, the median value for the pre-specified NIFm of the hazard ratio was 1.25 (n = 34; range 1.10-1.50). Among 55 positive trials, the median NIFm was 10.7% for categorical primary end points and 1.25 for time-to-event primary outcomes; for the 16 negative NIFCTs, the values were 15% and 1.28, respectively.
The purpose to conduct an NIFCT ( Table 2 ) was clear in 62 of 75 (83%) studies: 23 (30%) trials offered more convenient schedules (oral drugs, 'bolus' treatments), 15 (20%) provided less toxic drugs, 9 (12%) reported experimental drugs to be both less toxic and more conveniently administered, 11 (15%) offered less dose-intense regimens, and in two NIFCTs, the experimental therapy was a regimen with less drugs. Two trials tested the non-inferiority of a cheaper biosimilar agent. In 13 (17%) NIFCTs, a clear purpose to select a non-inferiority design was not identified. Among these 13 trials, 12 (92%) received funds from industry and 9 (69%) were positive as per the primary end point. When compared with the whole group of trials with clear purposes (n = 62), 20 (33%) received financial support from industry and 47 (77%) trials were positive. Eight of these 13 trials tested me too drugs such as setrons for nausea/vomiting (n = 6).
Among supportive care trials (n = 17), three (18%) did not report the pre-determined NIFm, all utilized a categorical end point, with a median value of 15% of absolute gain for the experimental arm against the control group. Similarly, of all therapeutic trials (n = 58), 10 (17%) provided the planned NIFm. Among them, 14 (24%) used a categorical end point, with a median absolute difference of 10% between the study arms, and 34 (57%) chose a time-to-event end point, with a median value for the pre-specified NIFm of the hazard ratio of 1.25. Therapeutic NIFCTs were often carried out to test more convenient (n = 25; 43%) or less toxic (n = 14; 24%) treatments. Supportive care trials were significantly more likely to lack a clear reason for being developed as an NIFCT when compared 
discussion
The present cross-sectional survey of NIFCTs of oncology therapies published in a decade shows that a significant proportion is sponsored by pharmaceutical companies and most offered more conveniently administered treatments and/ or less toxic drugs in comparison with the standard therapies. In nearly 20%, a clear purpose to choose a non-inferiority design could not be identified and this was more commonly seen among NIFCTs of supportive care agents. While the majority of trials yielded positive results, 17% did not provide pre-specified NIFm's and many trials used large NIFms to prove non-inferiority.
The number of NIFCTs testing anticancer therapies is increasing [8] . This likely reflects the great shift in investments toward the oncology drug development in the last few decades. Indeed, we have shown that approximately half of these trials received funds from the pharmaceutical industry. As shown here, an NIFCT usually enroll hundreds of patients, and that makes it an expensive and logistically complex enterprise where industry sponsorship is often needed.
Determination of the NIFm is a pivotal step to compute the sample size and one of the greatest challenges in the design and interpretation of the NIFCT. Here, we identified one out of 40 fully published articles and 22 of 34 abstracts which did not report pre-specified NIFms. Two recent surveys of NIFCTs in oncology observed smaller proportions (6% to 7%) of trials lacking description of this parameter [8, 9] . In our study, the reporting of the NIFm has not improved after the publication of the CONSORT guideline. The main implication of not reporting the NIFm is that the reader is unaware whether the Annals of Oncology original articles margin reported in the results was, in fact, set a priori. Post-hoc calculation of the NIFm is subject to methodological flaws such as increased types I (and consequent false claims) and II errors because of loss of power [10] . Another concerning finding was the somewhat large NIFm's used in some NIFCTs: the median NIFm for binary outcomes was 12.5% (the maximum the experimental arm could be worse than the standard treatment) and HR: 1.25 for time-toevent end points (the maximum HR the experimental arm could be worse than the standard treatment). Such effect sizes are often used to prove superiority in randomized cancer trials [11] . Examples of superiority trials with small effect sizes that led to drug approval include bevacizumab for ovarian cancer [12, 13] and erlotinib for pancreatic adenocarcinoma [14] . In contrast to superiority trials, where a large effect size makes it harder to achieve a positive result, in an NIFCT, the larger the margin, the more likely to prove non-inferiority and achieve a positive result [15] . This is problematic because an experimental agent can be interpreted as non-inferior when in fact, it is inferior. For example, if drug A (experimental) provides a 24% relative higher risk of death (HR) when compared with drug B (control treatment), drug A may be considered non-inferior to drug B if the NIFm falls within 1.25 but it may be actually worse if the NIFm was set at 1.2. Indeed, the non-inferiority margins set by the 55 positive trials were large: median of 11% for studies with binary primary end points and median 1.25 for those with time-to-event primary outcomes. The reasons to explain why the investigators used such large NIFms were beyond the scope of our study. It is possible that some investigators had budget constraints, limiting the number of patients to be enrolled, what, in turn, made them use larger NIFm's to calculate the sample size. Another possible reason is the will of sponsors and researchers to increase the chance of achieving positive results. This latter is tricky because, as discussed above, a drug with inferior efficacy could be erroneously considered non-inferior to standard of care. According to the Food and Administration Agency guidelines for non-inferiority trials, the choice of the NIFm should be based on the literature review or metaanalyses, if available, and clinical judgment [15] . But how to set its magnitude is arbitrary because there are no formal recommendations on how large an NIFm can be [10, 15] . Nevertheless, clinical research must have in mind that when they select an NIFm to calculate the sample size of a given NIFCT, this should be carefully evaluated in order to reduce type I error and not falsely conclude that an inferior drug is as good as the standard treatment.
In nearly 20% of an NIFCT, particularly among supportive care trials, a clear purpose to justify a non-inferiority design could not be recognized. This finding raises several ethical questions involving the non-inferiority design [16] [17] [18] . Patients participate in superiority clinical trials to potentially receive a better treatment. As for an NIFCT, patients are enrolled to treatments that are supposed to be similarly efficacious, or potentially worse, to conventional therapy, but which provide some advantages to them such as less toxic therapies or more conveniently administered medicines; alternatively, advantages of the NIFCT may benefit the society when less costly therapies are tested. Therefore, to participate in an NIFCT, with the risk of receiving a less effective therapy, without any perceived advantages, could go against one of the principles of ethics of medical research: the benefits of the experimental therapy must outweigh its risks [19] . We speculated that one of the purposes to conduct these NIFCTs was to evaluate me too drugs. Me too drugs are chemically similar pharmacological compounds with the same mechanism of action [20] . After evaluating each one of these trials, we found several NIFCTs which were testing me too drugs: five trials compared different types of setrons, 5HT3 inhibitors, for chemotherapy-induced nausea and vomiting, one trial tested two hormone therapies for breast cancer (the same mechanism of action), one NIFCT evaluated two strong opioids for cancer-related pain and one trial compared two antibiotics of the same pharmacological class for febrile neutropenia. Proponents of me too drugs argue that, due to competition, they may be a powerful tool to reduce the market price and lower the overall cost of treatment [20, 21] . Opponents reason that financial resources could be better off invested in the development of more innovative therapy [20, 21] .
The economic drivers of a pharmaceutical company to budget research and development to conduct an NIFCT likely follow the concept of a less risky path. For example, we found 10 industry-sponsored trials which investigated the noninferiority of different types of fluoropirimidines against 5-FU, a class of successful and widely utilized anticancer agents. On the other hand, most NIFCTs which tested less dose-intense regimens or regimens with a smaller number of drugs did not receive incentives by industry. This is troublesome because important clinical questions, as for instance, testing noninferiority of less expensive agents or comparing monotherapy versus polychemotherapy may not be answered as a result of lack of funding sources.
We are unaware of other studies that have evaluated the purposes underlying the design and conduction of an NIFCT in oncology. However, some limitations should be noted. The definition of the purpose of an NIFCT was based on the articles' text and clinical knowledge of investigators. Since 41 articles were in the abstract form, it is possible that some purposes were missed or misinterpreted. The best, but complex, way to elucidate this issue would be to carry out a structured and anonymous interview with sponsors and investigators. Also, because many studies were abstracts, data on source of funding was not accurate, and might have been underestimated. However, we decided to include abstracts because we believe that some clinical oncologists might take studies published in abstract form as relevant information for their treatment decision-making. Although we searched a decade of publications, the small sample precluded statistical inferences.
In conclusion, a non-inferiority design is a useful tool in the development of new cancer agents. However, they tend to rely on industry funding, many test me too drugs, often use large NIFm's and frequently present serious methodological problems. All these factors make the interpretation of cancer NIFCT a challenge for clinicians, investigators and regulatory agencies. We argue that NIFCTs should bring advantages to patients and/or society. To achieve that we urge investigators to set narrow NIFm's, as for example, HR of no greater than 20% for overall survival. Also, we encourage not for-profit funding original articles Annals of Oncology agencies help investigators to develop clinically important NIFCTs, particularly those that would result in less aggressive or less expensive regimens. Otherwise, treatments with inferior clinical efficacy may end up being used in clinical practice.
